Current Advances in the Management of Congenital Adrenal Hyperplasia.
Adv Pediatr
; 71(1): 135-149, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-38944479
ABSTRACT
Congenital adrenal hyperplasia (CAH) is an autosomal recessive genetic condition caused by various enzyme deficiencies that result in disruptions of pathways of adrenal steroidogenesis. 21-hydroxylase deficiency is the most common form of CAH and has a variable phenotype which ranges a spectrum, from the most severe salt-wasting type to the simple-virilizing type and the least severe nonclassical form. Patients with CAH are at risk for various comorbidities due to the underlying adrenal hormone production imbalance as well as the treatment of the condition, which typically includes supraphysiologic glucocorticoid dosing. Children and adults require frequent monitoring and careful medication dosing adjustment. However, there are multiple novel therapies on the horizon that offer promise to patients with CAH in optimizing their treatment regimens and reducing the risk of comorbidities.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Hiperplasia Suprarrenal Congênita
/
Glucocorticoides
Limite:
Child
/
Humans
Idioma:
En
Revista:
Adv Pediatr
/
Adv. pediatr
/
Advances in pediatrics
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos